FGF23 and hypophosphatemia: Conventional therapy for FGF23-mediated hypophosphatemia consists of multiple daily doses of oral phosphate and active vitamin D.<h4>Objective</h4>Burosumab is a fully human immunoglobulin G1 monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels and skeletal healing.